ClinicalTrials.gg
WithdrawnNCT05766488Updated Nov 12, 2026

Assessing Continuous Glucose Monitor Use in Underserved Primary Care Patients

An interventional study of Continuous Glucose Monitor (CGM) and Self-monitoring Blood Glucose (SMBG) in Type 2 Diabetes, sponsored by University of Nebraska. Withdrawn at 1 site in United States. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of Nebraska · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
poor accrual
Updated Nov 12, 2026Now WithdrawnStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States — 345 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
2,889th of 2,961
0 · median 90
Started
2023
with 144 others
No phase
1,242 of 3,308
200 open now
Registered
2,772nd of 3,308
by date

Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,889th largest by enrollment of the 2,961 interventional ones that give a count, is one of 145 that started in 2023, is one of 1,242 with no phase, and was the 2,772nd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

345 of the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

340 more — sign in →

All 345 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

Continuous glucose monitoring (CGM) has demonstrated improved outcomes in both type 1 and type 2 diabetes populations in comparison to traditional methods; however, these devices have not been well studied in underserved adult patients (e.g., low-income, uninsured) who may face additional barriers to monitoring. Furthermore, there is limited data exploring long-term (3- to 6- month) health care team-based management of these devices in the primary care setting. The purpose of this study is to further understand the benefits and barriers associated with CGM use in underserved populations with type 2 diabetes and improve their overall diabetes care.

Read the detailed description

Continuous glucose monitoring (CGM) has demonstrated improved outcomes in both type 1 and type 2 diabetes populations in comparison to traditional methods; however, these devices have not been well studied in underserved adult patients (e.g., low-income, uninsured) who may face additional barriers to monitoring. Furthermore, there is limited data exploring long-term (3- to 6- month) health care team-based management of these devices in the primary care setting. This study will evaluate the perceived and experienced benefits and barriers of continuous glucose monitor (CGM) and traditional glucometer use and identify diabetes related outcomes associated with CGM use relative to usual care with self-monitoring of blood glucose (SMBG) in an underserved population.

Eligible adult (>=19 years of age) patients at participating clinics with type 2 diabetes, A1c >=9%, and concomitant insulin therapy and/or using two or more diabetes medications will be randomly enrolled to one of two groups: Freestyle Libre 2 CGM or traditional glucometer. Pre- and post-surveys will be used to evaluate perceived and experienced benefits and barriers to CGM use and diabetes-related outcomes will be compared between the groups using face-to-face, telephonic, and/or digital avenues. The latter aim will replicate current processes of team-based diabetes care which is blood glucose management from a pharmacist under collaborative practice with the primary care physician. Follow-up will also replicate these clinic processes throughout the 6-month period, including telephone calls and monthly in-clinic visits.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes
  • A1c >9% at recruitment
  • On/initiating insulin or on two or more diabetes medications

Exclusion criteria

Exclusion Criteria:

  • Current use of an insulin pump
  • On dialysis
  • Pregnant
  • Implanted medical device (e.g., pace-maker, defibrillator)
  • Intellectual or physical disabilities that may interfere with ability to properly use the Continuous Glucose Monitor (CGM)
  • Able to read English
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Continuous Glucose Monitoring

    Participants will use a Freestyle Libre 2 monitoring device for 6 months to track blood glucose levels.

    Device: Continuous Glucose Monitor (CGM)

  • Active comparator
    Traditional Glucometer Arm

    Participants will use a traditional glucose monitoring device (glucometer) to self-monitor their blood glucose for 6 months to track blood glucose levels.

    Device: Self-monitoring Blood Glucose (SMBG)

Interventions

  • DeviceContinuous Glucose Monitor (CGM)

    A Freestyle Libre 2 continuous glucose monitor (CGM) will be provided in the experimental arm of this study for 6 months.

    Also known as: Flash-glucose Monitor

  • DeviceSelf-monitoring Blood Glucose (SMBG)

    A traditional glucometer device will be assigned in the active comparitor arm of this study for 6 months.

    Also known as: Traditional glucometer

06

What researchers measure

Primary outcomes

  1. Glycemic Control (Hemoglobin A1c)

    Glycemic control will be assessed by measuring hemoglobin A1c at baseline, 3 months, and 6 months. Values will be evaluated as a continuous variable and categorized as \<7.0% vs \>7.0% to \<9.0% and \>9.0%. Comparisons of the proportions of participants achieving a minimum of 1 point drop in hemoglobin A1c will be made between study arms.

    Time frame: Baseline, 3 months, and 6 months.

Secondary outcomes

  1. Hypoglycemia

    Continuous glucose monitor (CGM) and glucometer blood glucose data will be evaluated to determine number and percentage of hypoglycemic readings (i.e., \<70 mg/dL). For CGM data, % time within target range, % time below specific thresholds for hypoglycemia) will be captured and described.

    Time frame: 6 months

  2. Hyperglycemia

    Continuous glucose monitor (CGM) and glucometer blood glucose data will be evaluated to determine percentage of hyperglycemic values (i.e., \>180 mg/dl) experienced. For CGM data, % time within target range, % time below specific thresholds for hypoglycemia) will be captured and described.

    Time frame: 6 months

  3. Blood Glucose Capture Rate

    Number of days without any blood glucose recordings will be captured as a percentage over the study period.

    Time frame: 6 months

  4. Perceived or Experienced Benefits and Barriers to Device Use

    A pre- and post-survey will be provided to all participants to qualitatively identify benefits and barriers to access and use of their assigned device and willingness to continue CGM use (follow-up survey).

    Time frame: Baseline and 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Jul 2026, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2023
First posted
Mar 13, 2023
StartActual
Jul 23, 2023
Primary completionActual
Jul 20, 2026
CompletionActual
Jul 20, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Withdrawn poor accrual
changed Nov 12, 2026
Start date
Jul 24, 2023→Jul 23, 2023
Nov 12, 2026
Enrollment
50 (estimated)→0 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Enrolling by invitation→Withdrawn
    Why stopped poor accrual
    Start date Jul 24, 2023→Jul 23, 2023
    Enrollment 50 (estimated)→0 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05766488
Collaborators
Great Plains IDeA-CTR
Responsible party
Sponsor
First posted
Mar 13, 2023
Start date
Jul 23, 2023
Primary completion
Jul 20, 2026
Completion
Jul 20, 2026
Last update
Nov 12, 2026

Study contacts

Drew C Prescott, PharmD
principal investigator · University of Nebraska

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion